[

Having a preexisting autoimmune disease is an independent risk factor for poor outcomes with myelodysplastic syndrome (MDS), according to a study published in the June issue of Clinical Immunology.
Ning Wu, from the Peking University Institute of Hematology and National Clinical Research Center for Hematologic Disease in Beijing, and colleagues retrospectively studied 161 patients with MDS undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) from 2013 to 2024, including 39 patients with preexisting autoimmune disease and 122 matched controls, to understand the combined impact on allo-HSCT.
The researchers found that patients with an autoimmune disease had significantly lower platelet engraftment, a higher relapse rate, inferior leukemia-free survival, and graft-versus-host disease (GVHD)-free, relapse-free survival (GRFS). There were no significant differences observed in overall survival or acute or chronic GVHD. Active autoimmune disease at transplantation conferred higher relapse and worse GRFS in a subgroup analysis.
“Preexisting autoimmune disease is an independent risk factor for poor outcomes, supporting personalized strategies for this high-risk population,” the authors write.
Publication details
Ning Wu et al, The impact of pre-existing autoimmune diseases in myelodysplastic syndrome patients undergoing allogeneic hematopoietic stem cell transplantation: A retrospective cohort study, Clinical Immunology (2026). DOI: 10.1016/j.clim.2026.110710
Journal information:
Clinical Immunology
Clinical categories
Copyright © 2026 HealthDay. All rights reserved.
Citation:
Autoimmune disease linked to poor outcomes with myelodysplastic syndrome (2026, May 29)
retrieved 29 May 2026
from https://medicalxpress.com/news/2026-05-autoimmune-disease-linked-poor-outcomes.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.
